Related Experiment Videos
Antiangiogenic therapy in multiple myeloma
1Institute of Hematology and Medical Oncology 'Seràgnoli', Bologna University, Bologna, Italy. ptosi@med.unibo.it
Acta Haematologica
|January 30, 2002
Summary
Thalidomide shows promise in treating multiple myeloma (MM) by inhibiting blood vessel growth. Combinations with other drugs enhance its effectiveness in relapsed or refractory MM patients.
Area of Science:
- Oncology
- Hematology
- Pharmacology
Background:
- Multiple myeloma (MM) progression involves increased bone marrow neovascularization.
- Targeting angiogenesis, the formation of new blood vessels, is a potential therapeutic strategy for MM.
Purpose of the Study:
- To evaluate the efficacy of thalidomide and its combinations in treating multiple myeloma.
- To explore the antiangiogenic mechanisms of thalidomide in MM.
Main Methods:
- Review of evidence on thalidomide's efficacy in relapsed/refractory MM.
- Analysis of ongoing studies on thalidomide-based drug combinations (e.g., with dexamethasone, chemotherapy).
- Assessment of in vitro and animal model data for thalidomide analogs and other antiangiogenic agents.
Main Results:
- Thalidomide demonstrated a 30-40% response rate in relapsed/refractory MM with mild toxicity.
- Thalidomide-based combinations showed synergistic effects, with response rates of 50-70% in pretreated patients.
- Thalidomide analogs and other antiangiogenic compounds show promising activity.
Conclusions:
- Thalidomide is an effective agent in MM, likely through antiangiogenic, immunomodulatory, and anti-cytokine mechanisms.
- Thalidomide-based combinations offer improved response rates in MM treatment.
- Novel antiangiogenic compounds, including thalidomide analogs, represent a promising future direction for MM therapy.